A Phase I Trial of Capecitabine in Combination With Cemiplimab in Patients With Hormone Receptor Positive Metastatic Breast Cancer
Latest Information Update: 21 Mar 2024
At a glance
- Drugs Capecitabine (Primary) ; Cemiplimab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions
- 18 Mar 2024 Planned End Date changed from 9 Dec 2025 to 9 Sep 2025.
- 18 Mar 2024 Planned primary completion date changed from 9 Dec 2024 to 9 Sep 2024.
- 09 Feb 2023 Planned End Date changed from 1 Sep 2024 to 9 Dec 2025.